Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment.

ABSTRACT:

Objective

Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.

Methods

Patients with systemic lupus erythematosus (SLE) (n = 268) undergoing clinically indicated kidney biopsies (urine protein/creatinine ratio [UPCR] ≥ 0.5) were recruited through the AMP Rheumatoid Arthritis and SLE Network. Serum was collected at biopsy and 3-, 6-, and 12-month postbiopsy, alongside samples from 22 healthy controls. Concentrations of 66 immune mediators were quantified using xMAP multiplex assays, and (TACE) measured by enzyme-linked immunosorbent assay. Seven mediators with

SUBMITTER: Fava A 

PROVIDER: S-EPMC12767624 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature